DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma · Refractory Multiple Myeloma · Relapse Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Contact: Study coordinator (David Avigan, MD) · davigan@bidmc.harvard.edu · 617-667-9920
Contact: Principal Investigator (David Avigan, MD)

Study leads

Jacalyn Rosenblatt, MD
Principal Investigator
Beth Israel Deaconess Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Iowa City, United States

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingEARLY_PHASE1

West Hollywood, United States

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Xi’an, China

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Neoplasms, Plasma Cell · Neoplasms by Histologic Type · Neoplasms

Abroad (travel likely)RecruitingPHASE1

Atlanta, United States